'Looking for clarity on forward path from Type A meeting,' target $25.
https://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Downgrades+Acadia+Pharmaceuticals+%28ACAD%29+to+Neutral%2C+Looking+for+clarity+on+forward+path+from+Type+A+meeting/18223034.html
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.